Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06036992

Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common: intracystic haemorrhage, renal or hepatic cyst infections, cyst-related mechanical complications and lithiasis. To date, there is no reliable epidemiological data on the frequency and clinical impact of these complications. Diagnosis of these complications is often complicated, and their management has not been codified. The latest international recommendations (KDIGO) provide only low-level recommendations. For the most complex cases (recurrent cystic infections, resistant pain, mechanical complications and malnutrition, need for pre-transplant nephrectomy, etc.), practitioners are often at a loss and management varies greatly from one centre to another.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common: intracystic haemorrhage, renal or hepatic cyst infections, cyst-related mechanical complications and lithiasis. To date, there is no reliable epidemiological data on the frequency and clinical impact of these complications. Diagnosis of these complications is often complicated, and their management has not been codified. The latest international recommendations (KDIGO) provide only low-level recommendations. For the most complex cases (recurrent cystic infections, resistant pain, mechanical complications and malnutrition, need for pre-transplant nephrectomy, etc.), practitioners are often at a loss and management varies greatly from one centre to another.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with autosomal dominant polycystic kidney disease (APKD) participating in the Genkyst study
  • Patient with at least one cystic complication. The cystic complications retained are the following:
  • Acute or chronic cyst-related pain requiring analgesic treatments
  • Cyst infection
  • Intracystic haemorrhage
  • Urinary lithiasis
  • Functional complaints related to the cystic mass: digestive disorders with eating disorders, undernutrition, diaphragmatic compression phenomena, portal hypertension, umbilical or linea alba hernias, ventrations
  • Need for a cystic reduction procedure: puncture, marsupialization, open surgery (including preparation for grafting)

Exclusion criteria

  • Patients who have expressed their opposition to taking part in the study
  • Patient under legal protection (guardianship, curatorship, etc.)

Treatment and study plan

Primary outcomes

  1. To improve knowledge of the epidemiology of cystic complications within the Genkyst network

    Time frame: 12 months

    number of cases of cystic complications per year per complication

Secondary outcomes

  1. Creation of a specific multidisciplinary consultation meeting

    Time frame: 12 months

    Meetings and exchanges between different health professionals: interventional radiologists, surgeons, infectiologists, hepatologists, pain specialists and nephrologists to discuss the best possible management for patients with complex cystic complications.

  2. Creation of an image bank

    Time frame: 12 months

    consulting images to recalculate and improve diagnostic scores

  3. Creation of a group of control patients

    Time frame: 12 months

    the change from baseline in quality of life scores at 1 year.

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: COMPLIK

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Sep 14, 2023
Registry last updated
Aug 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.